Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
West Hills, CA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
West Hills, CA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Kissimmee, FL
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
mi
from
Arkansas City, KA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
mi
from
Arkansas City, KA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Butte, MT
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Binghamton, NY
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Binghamton, NY
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fayetteville, NC
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fayetteville, NC
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
mi
from
Springdale, OH
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
mi
from
Springdale, OH
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Medford, OR
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Beaver, PA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Beaver, PA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Mount Pleasant, SC
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Memphis, TN
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Federal Way, WA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Federal Way, WA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Renton, WA
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Renton, WA
Click here to add this to my saved trials
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated:  8/1/2016
mi
from
Camperdown,
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Status: Enrolling
Updated: 8/1/2016
mi
from
Camperdown,
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chandler, AZ
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oviedo, FL
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oviedo, FL
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Nampa, ID
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Nampa, ID
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Evansville, IN
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Butte, MT
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Canton, OH
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Portland, OR
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Greer, SC
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Midland, TX
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Midland, TX
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated:  8/1/2016
mi
from
Tallinn,
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.
Status: Enrolling
Updated: 8/1/2016
mi
from
Tallinn,
Click here to add this to my saved trials
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cypress, CA
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cypress, CA
Click here to add this to my saved trials
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Austin, TX
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated:  8/1/2016
mi
from
Bratislava,
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Status: Enrolling
Updated: 8/1/2016
mi
from
Bratislava,
Click here to add this to my saved trials
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tacoma, WA
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Palm Springs, CA
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chiefland, FL
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chiefland, FL
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Olive Branch, MS
A Study of Aleglitazar in Patients With Type 2 Diabetes
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Olive Branch, MS
Click here to add this to my saved trials